## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($328.69)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Cencora Bets Big on Oncology Platform in $5 Billion OneOncology Deal**
- Source: MyChesCo | 20251228T030808 | Somewhat-Bullish | Relevance: 100%
- Cencora, Inc. has agreed to acquire the majority of the outstanding equity in OneOncology it does not already own for an equity value of approximately $6 billion and a total cash consideration of roughly $5.0 billion. This acquisition reinforces Cencora's strategy to expand its management services organization in physician-led specialty care, particularly oncology, and is expected to strengthen its specialty solutions and improve patient access to pharmaceuticals and clinical trials. The deal is projected to be neutral to adjusted diluted earnings per share in the first 12 months post-closing and is anticipated to close by the end of Cencoraâ€™s fiscal 2026 second quarter.

**2. Cencora Stock: Quiet Rally, Firm Fundamentals and a Market Looking for the Next Catalyst**
- Source: AD HOC NEWS | 20251230T150242 | Bullish | Relevance: 100%
- Cencora (NYSE: COR) has seen a quiet but steady rally, outperforming other healthcare distributors due to firm fundamentals and positive analyst sentiment. The stock is trading near its 52-week high, with investors recognizing its role as a high-quality compounder in healthcare logistics. Analysts maintain largely positive views, with consensus price targets suggesting continued upside for the company.

**3. Pacer Advisors Inc. Sells 880,384 Shares of Cencora, Inc. $COR**
- Source: MarketBeat | 20251230T105610 | Neutral | Relevance: 100%
- Pacer Advisors Inc. significantly reduced its stake in Cencora (NYSE:COR) by 97.8%, selling 880,384 shares in Q3, but still holds 20,187 shares valued at $6.31 million. Insiders EVP Silvana Battaglia and CEO Robert P. Mauch also sold shares in December, totaling 20,317 shares worth approximately $7.01 million over the last three months, though insiders still own 10.8% of the company. Wall Street analysts maintain a "Moderate Buy" rating with a consensus target price of $373.25, with some firms raising their price targets after Cencora reported strong Q3 earnings and increased its dividend.

**4. Here's What We Like About Cardinal Health's (NYSE:CAH) Upcoming Dividend**
- Source: Simply Wall Street | 20251228T121259 | Neutral | Relevance: 63%
- Cardinal Health (NYSE:CAH) is poised to go ex-dividend soon, offering a dividend payment of US$0.5107 per share, contributing to a 1.0% trailing yield. The company demonstrates strong dividend sustainability with a modest payout ratio of 31% from profit and 11% from free cash flow, alongside robust earnings growth of 23% per annum over the past five years. This favorable combination of rapid earnings growth, low payout ratios, and consistent dividend increases suggests Cardinal Health is a solid choice for dividend-focused investors.

**5. Here's Why You Should Retain Glaukos Stock in Your Portfolio Now**
- Source: Finviz | 20251229T160921 | Somewhat-Bullish | Relevance: 60%
- Glaukos Corporation is well-positioned for growth due to the successful launch of its iDose TR product and its robust product pipeline, despite facing stiff competition. The company's shares have significantly outperformed the industry this year, driven by strong adoption of iDose TR and the recent FDA approval of Epioxa, which is set to boost its corneal health franchise. While reimbursement complexities and a temporary revenue disruption during the Epioxa transition pose challenges, Glaukos' diversified global growth, strong financial profile, and ongoing innovation support its positive outlook.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.81 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $66.0B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.81 |
| Forward P/E | 17.4 |
| Current P/E | 19.4 |
| YoY Growth | 11.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.9% to -0.7% (+1.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.6pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). RSI neutral at 44. OFD pattern: -SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.65% (CS: 41) | Neutral |
| RSI_14 | 43.7 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 0.977x | Below |
| vs SMA200 | 1.113x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $340.09
- **Stop Loss:** $328.69 (3.4% risk)
- **Target:** $351.49 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 115
- **Position Value:** $39,110.35
- **Portfolio %:** 39.11%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*